Tris Pharma

Tris Pharma, Inc. is a biopharmaceutical company based in Monmouth Junction, New Jersey, founded in 2000. It ranks as the third-largest specialty pharmaceutical company in the United States and employs over 500 people. The company focuses on the research, development, and manufacturing of both over-the-counter and prescription branded products, as well as specialty generic products. Tris Pharma is dedicated to developing innovative therapies, particularly in the areas of ADHD, pain, addiction, and central nervous system disorders. The company utilizes its proprietary LiquiXR technology to create unique therapeutic approaches and has a strong pipeline of investigational therapies. Recently, it received FDA approval for Onyda XR, a liquid non-stimulant treatment for pediatric ADHD. With over 150 U.S. and international patents, Tris Pharma demonstrates a commitment to innovation and addressing unmet patient needs.